INTERCEPT PHARMACEUTICALS, INC.
- Tickers
- None listed
- Headquarters
- Not recorded
- SEC CIK
- 0001270073
- Website
- Not recorded
Closing prices
This company has no stock ticker on record, so there are no prices to show.
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| Linerixibat | Not recorded | Approved | None scheduled | 0 | |
| Obeticholic acid | Compensated Cirrhosis; Non Alcoholic Steatohepatitis (NASH); Nonalcoholic Steatohepatitis; Primary Biliary Cirrhosis | Approved | None scheduled | 3 |
FDA-approved applications
| Application | Brand names | Active ingredients | First approved | Status |
|---|---|---|---|---|
| NDA 220295 | LYNAVOY | LINERIXIBAT | Prescription | |
| NDA 207999 | OCALIVA | OBETICHOLIC ACID | Discontinued |
Open in the approved-drug database for INTERCEPT PHARMACEUTICALS, INC.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 88,789,000 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −2,790,000 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 41,513,000 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | 93,408,000 USD | 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 10-Q for Operating expenses on sec.gov (opens in a new tab)Filed |
| Cash and cash equivalents | 102,736,000 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | 351,801,000 USD | At 30 Sep 2021 FY2021 Q3 | 10-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed |
| Total liabilities | 321,317,000 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | 71,845,000 USD | At 30 Sep 2023 FY2023 Q3 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 41,825,966 shares | At 2 Nov 2023 FY2023 Q3 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Jul 2023 to 30 Sep 2023 FY2023 Q3 | 88,789,000 USD | 10-Q filed 6 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2023 to 30 Jun 2023 FY2023 Q2 | 83,718,000 USD | 10-Q filed 2 Aug 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2023 to 31 Mar 2023 FY2023 Q1 | 67,958,000 USD | 10-Q filed 27 Apr 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2022 to 31 Dec 2022 FY2022 | 285,710,000 USD | 10-K filed 2 Mar 2023 on sec.gov (opens in a new tab)Filed |
| 1 Oct 2022 to 31 Dec 2022 FY2022 | 77,219,000 USD | 10-K filed 2 Mar 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jul 2022 to 30 Sep 2022 FY2023 Q3 | 77,588,000 USD | 10-Q filed 6 Nov 2023 on sec.gov (opens in a new tab)Filed |
| 1 Apr 2022 to 30 Jun 2022 FY2023 Q2 | 71,757,000 USD | 10-Q filed 2 Aug 2023 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2022 to 31 Mar 2022 FY2023 Q1 | 59,146,000 USD | 10-Q filed 27 Apr 2023 on sec.gov (opens in a new tab)Filed |
The newest 12 periods of each metric are listed; older ones are on sec.gov.
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for INTERCEPT PHARMACEUTICALS, INC. on Insider TradesLast 90 days of Form 4 filings, from 4 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.